Interaction Guide · Research summary

Can I take Radix Et Rhizoma Valerianae with Alprazolam?

Review Radix Et Rhizoma Valerianae with Alprazolam: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Identify the valerian species and extract before using this root product with alprazolam. Evidence for one Valeriana officinalis preparation cannot settle the safety of an unspecified root product.

What this answer covers

Radix et Rhizoma Valerianae remains species-ambiguous; V. officinalis study applies only to the identified extract.

Supplement or preparation
Radix et Rhizoma Valerianae
Medication ingredient
alprazolam

Resolve the root name first

Ask for the Latin species, root or rhizome content and extract details. An unspecified valerian-root name is not enough to identify a study product.

What the direct pharmacokinetic study found

A specific Valeriana officinalis extract modestly increased alprazolam’s peak concentration, but did not significantly change overall exposure or half-life. This does not establish a major metabolism interaction for every valerian product.

Blood levels are not the whole safety question

That study did not establish absence of combined drowsiness. For confirmed Valeriana officinalis, guidance advises against sedative co-use; no protective interval is established.

Protect your alertness

Alprazolam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.

Evidence and practical considerations

Side effects & toxicity

Unresolved botanical identity prevents an exact broad avoidance/sedation conclusion. Species-confirmed guidance supports a conditional alertness precaution.

Exact scope
Radix et Rhizoma Valerianae remains species-ambiguous; V. officinalis study applies only to the identified extract. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
Medication form and route
oral; other cannabis routes only if explicitly discussed
Timing or duration
Exact duration and dose depend on source; single-dose and chronic use are distinguished.

What remains uncertain

  • Direct V. officinalis PK study found modest peak change but no significant total exposure change; it was not an additive sedation safety study.

Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral alprazolam.

CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.

How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.

Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Possible but unproven sleep-inducing effect; advises against use with alcohol or sedatives. Mental dullness can occur; long-term safety is uncertain.

How this applies: Preparation-specific context; not a directly measured alprazolam interaction.

No alprazolam interaction trial. Chronic use can be followed by withdrawal symptoms when stopped abruptly.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twelve healthy volunteers.

Alprazolam peak concentration increased modestly, but AUC and elimination half-life did not change significantly.

How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.

PK study is not a clinical sedation safety trial. Exact extract/species cannot resolve an unidentified valerian-root inventory item.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries.
Research summary published

Article revision: 7ec6ad1d27aa87fc

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.